Table I.
Clinicopathological features of ENKTL stratified according to CD30 expression.
| Characteristic | Overall, n (%) | CD30+, n (%) | CD30−, n (%) | P-value |
|---|---|---|---|---|
| Gender | ||||
| Male | 84 (68.9) | 12 (66.7) | 72 (69.2) | 0.828 |
| Female | 38 (31.1) | 6 (33.3) | 32 (30.8) | |
| Age, years | ||||
| ≤60 | 97 (79.5) | 15 (83.3) | 82 (78.8) | 0.663 |
| >60 | 25 (20.5) | 3 (16.7) | 22 (21.2) | |
| B symptoms | ||||
| Absence | 57 (46.7) | 10 (55.6) | 47 (45.2) | 0.416 |
| Presence | 65 (53.3) | 8 (44.4) | 57 (54.8) | |
| Elevated serum LDH | ||||
| Yes | 49 (40.2) | 9 (50.0) | 40 (38.5) | 0.357 |
| No | 73 (59.8) | 9 (50.0) | 64 (61.5) | |
| Bone marrow involvement | ||||
| Yes | 3 (2.5) | 1 (5.6) | 2 (1.9) | 0.358 |
| No | 119 (97.5) | 17 (94.4) | 102 (98.1) | |
| Ann Arbor staging | ||||
| I, II | 80 (65.6) | 14 (77.8) | 66 (63.5) | 0.238 |
| III, IV | 42 (34.4) | 4 (22.2) | 38 (36.5) | |
| Histological types | ||||
| SC | 27 (22.1) | 4 (22.2) | 23 (22.1) | 0.540 |
| MC | 65 (53.3) | 8 (44.4) | 57 (54.8) | |
| LC | 10 (8.2) | 3 (16.7) | 7 (6.7) | |
| PC | 20 (16.4) | 3 (16.7) | 17 (16.3) | |
| Necrosis | ||||
| Yes | 105 (86.1) | 17 (94.4) | 88 (84.6) | 0.266 |
| No | 17 (13.9) | 1 (5.6) | 16 (15.4) | |
| Vascular destruction | ||||
| Yes | 45 (36.9) | 8 (44.4) | 37 (35.6) | 0.472 |
| No | 77 (63.1) | 10 (55.6) | 67 (64.4) |
P-values were calculated from a χ2 test. B symptoms are defined as weight loss of >10% within 6 months, night sweats and fever of unknown origin. CD30, tumor cell necrosis factor superfamily member 8; ENKTL, extranodal natural killer/T cell-cell lymphoma; LDH, lactic dehydrogenase; SC, small cell type; MC, medium-sized cell type; LC, large cell type; PC, pleomorphic cell type.